Does the media favor CRDF or FDMT?

In the previous week, Cardiff Oncology had 2 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.54 beat Cardiff Oncology's score of 0.06 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral 4D Molecular Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KYTX or CRDF?

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 6 mentions for Cardiff Oncology. Kyverna Therapeutics' average media sentiment score of 0.33 beat Cardiff Oncology's score of 0.06 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CRDF or OVID?

In the previous week, Cardiff Oncology had 3 more articles in the media than Ovid Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 3 mentions for Ovid Therapeutics. Cardiff Oncology's average media sentiment score of 0.06 beat Ovid Therapeutics' score of -0.19 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CTNM or CRDF?

In the previous week, Cardiff Oncology had 5 more articles in the media than Contineum Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 1 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.93 beat Cardiff Oncology's score of 0.06 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Cardiff Oncology (CRDF) Competitors

$1.55 +0.15 (+10.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.54 -0.02 (-0.97%)

As of 05:16 PM Eastern

Compare

CRDF vs. FDMT, KYTX, OVID, CTNM, and AQST

Should you buy Cardiff Oncology stock or one of its competitors? MarketBeat compares Cardiff Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiff Oncology include 4D Molecular Therapeutics (FDMT), Kyverna Therapeutics (KYTX), Ovid Therapeutics (OVID), Contineum Therapeutics (CTNM), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.

How does Cardiff Oncology compare to 4D Molecular Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

In the previous week, Cardiff Oncology had 2 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.54 beat Cardiff Oncology's score of 0.06 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 8.5% of Cardiff Oncology shares are held by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cardiff Oncology currently has a consensus target price of $8.75, suggesting a potential upside of 464.52%. 4D Molecular Therapeutics has a consensus target price of $29.88, suggesting a potential upside of 198.45%. Given Cardiff Oncology's higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

4D Molecular Therapeutics has a net margin of -182.34% compared to Cardiff Oncology's net margin of -8,527.43%. 4D Molecular Therapeutics' return on equity of -36.83% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%

Cardiff Oncology has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market.

Cardiff Oncology has higher earnings, but lower revenue than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	179.62	-$45.85M	-$0.67	N/A
4D Molecular Therapeutics	$85.21M	6.14	-$140.11M	-$2.57	N/A

Summary

4D Molecular Therapeutics beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Kyverna Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 277.36%. Cardiff Oncology has a consensus price target of $8.75, indicating a potential upside of 464.52%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Kyverna Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 7 mentions for Kyverna Therapeutics and 6 mentions for Cardiff Oncology. Kyverna Therapeutics' average media sentiment score of 0.33 beat Cardiff Oncology's score of 0.06 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Cardiff Oncology has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Cardiff Oncology	$590K	179.62	-$45.85M	-$0.67	N/A

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kyverna Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Kyverna Therapeutics' return on equity of -81.88% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Summary

Kyverna Therapeutics beats Cardiff Oncology on 10 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to Ovid Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ovid Therapeutics has a net margin of -240.11% compared to Cardiff Oncology's net margin of -8,527.43%. Ovid Therapeutics' return on equity of -22.51% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Cardiff Oncology has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Cardiff Oncology presently has a consensus price target of $8.75, suggesting a potential upside of 464.52%. Ovid Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 106.65%. Given Cardiff Oncology's higher probable upside, equities analysts plainly believe Cardiff Oncology is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Cardiff Oncology had 3 more articles in the media than Ovid Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 3 mentions for Ovid Therapeutics. Cardiff Oncology's average media sentiment score of 0.06 beat Ovid Therapeutics' score of -0.19 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ovid Therapeutics has higher revenue and earnings than Cardiff Oncology. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	179.62	-$45.85M	-$0.67	N/A
Ovid Therapeutics	$7.25M	63.84	-$17.41M	-$0.29	N/A

Summary

Ovid Therapeutics beats Cardiff Oncology on 10 of the 17 factors compared between the two stocks.

How does Cardiff Oncology compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Cardiff Oncology has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	9.23	-$59.98M	-$1.95	N/A
Cardiff Oncology	$590K	179.62	-$45.85M	-$0.67	N/A

Contineum Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Contineum Therapeutics' return on equity of -27.09% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

16.3% of Cardiff Oncology shares are owned by institutional investors. 11.3% of Contineum Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Contineum Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Contineum Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 62.07%. Cardiff Oncology has a consensus price target of $8.75, suggesting a potential upside of 464.52%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Cardiff Oncology had 5 more articles in the media than Contineum Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 1 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.93 beat Cardiff Oncology's score of 0.06 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Cardiff Oncology beats Contineum Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Aquestive Therapeutics currently has a consensus price target of $8.80, indicating a potential upside of 112.56%. Cardiff Oncology has a consensus price target of $8.75, indicating a potential upside of 464.52%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aquestive Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

In the previous week, Cardiff Oncology had 6 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 6 mentions for Cardiff Oncology and 0 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.89 beat Cardiff Oncology's score of 0.06 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aquestive Therapeutics	Very Positive
Cardiff Oncology	Neutral

Cardiff Oncology has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	11.66	-$83.78M	-$0.61	N/A
Cardiff Oncology	$590K	179.62	-$45.85M	-$0.67	N/A

Aquestive Therapeutics has a net margin of -137.08% compared to Cardiff Oncology's net margin of -8,527.43%. Aquestive Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%

Summary

Aquestive Therapeutics beats Cardiff Oncology on 11 of the 17 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDF vs. The Competition

Export

Metric	Cardiff Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$105.97M	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-2.31	18.78	23.87	24.36
Price / Sales	179.62	320.80	521.52	117.07
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	2.31	6.80	9.99	6.73
Net Income	-$45.85M	$24.09M	$3.56B	$337.03M
7 Day Performance	-15.76%	-2.56%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-57.18%	48.90%	28.77%	33.98%

Cardiff Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDF Cardiff Oncology	2.2089 of 5 stars	$1.55 +10.7%	$8.75 +464.5%	-60.1%	$105.97M	$590K	N/A	20	News Coverage Analyst Downgrade
FDMT 4D Molecular Therapeutics	2.3042 of 5 stars	$9.71 -2.0%	$29.88 +207.7%	+146.3%	$518.06M	$85.21M	N/A	120	News Coverage
KYTX Kyverna Therapeutics	2.0058 of 5 stars	$8.22 -3.5%	$30.00 +265.0%	+180.3%	$517.97M	N/A	N/A	96	News Coverage Analyst Forecast
OVID Ovid Therapeutics	2.3307 of 5 stars	$2.56 -6.2%	$5.13 +100.2%	+700.1%	$509.53M	$7.12M	N/A	60	News Coverage
CTNM Contineum Therapeutics	3.509 of 5 stars	$13.09 -3.0%	$20.00 +52.8%	+163.6%	$504.34M	N/A	N/A	31	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDF) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiff Oncology (CRDF) Competitors

CRDF vs. FDMT, KYTX, OVID, CTNM, and AQST

How does Cardiff Oncology compare to 4D Molecular Therapeutics?

Summary

How does Cardiff Oncology compare to Kyverna Therapeutics?

Summary

How does Cardiff Oncology compare to Ovid Therapeutics?

Summary

How does Cardiff Oncology compare to Contineum Therapeutics?

Summary

How does Cardiff Oncology compare to Aquestive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiff Oncology (CRDF) Competitors

CRDF vs. FDMT, KYTX, OVID, CTNM, and AQST

How does Cardiff Oncology compare to 4D Molecular Therapeutics?

Does the media favor CRDF or FDMT?

Do insiders and institutionals hold more shares of CRDF or FDMT?

Do analysts recommend CRDF or FDMT?

Is CRDF or FDMT more profitable?

Which has more volatility and risk, CRDF or FDMT?

Which has better earnings & valuation, CRDF or FDMT?

Summary

How does Cardiff Oncology compare to Kyverna Therapeutics?

Do analysts prefer KYTX or CRDF?

Which has more volatility and risk, KYTX or CRDF?

Does the media prefer KYTX or CRDF?

Which has preferable valuation and earnings, KYTX or CRDF?

Do insiders & institutionals hold more shares of KYTX or CRDF?

Is KYTX or CRDF more profitable?

Summary

How does Cardiff Oncology compare to Ovid Therapeutics?

Do institutionals & insiders hold more shares of CRDF or OVID?

Is CRDF or OVID more profitable?

Which has more risk and volatility, CRDF or OVID?

Do analysts prefer CRDF or OVID?

Does the media refer more to CRDF or OVID?

Which has stronger valuation & earnings, CRDF or OVID?

Summary

How does Cardiff Oncology compare to Contineum Therapeutics?

Which has higher valuation and earnings, CTNM or CRDF?

Is CTNM or CRDF more profitable?

Do insiders and institutionals hold more shares of CTNM or CRDF?

Which has more volatility & risk, CTNM or CRDF?

Do analysts prefer CTNM or CRDF?

Does the media refer more to CTNM or CRDF?

Summary

How does Cardiff Oncology compare to Aquestive Therapeutics?

Do analysts rate AQST or CRDF?

Do institutionals and insiders believe in AQST or CRDF?

Which has more volatility and risk, AQST or CRDF?

Does the media refer more to AQST or CRDF?

Which has stronger valuation and earnings, AQST or CRDF?

Is AQST or CRDF more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools